ABSTRACT
The bronchodilatory effect of maprotiline (Ludiomil, firm Ciba-Geigy) was investigated in 20 patients with bronchospasm (FEV %below 60%). The effect of a single dose of 75 mg maprotiline was compared with that produced by 500 mg of aminophylline, applied each time in 500 ml normal saline during 90 min, on two different days, in randomized sequence, always at the same day time. Prior to and at 5, 10, 20, 30, 60, 90, 120, 150 and 180 minutes after commencement of the infusion the following parameters of pulmonary ventilation have been determined: VC, FEV1, FEV1%., MEFR and MBC. The stated differences between the efficacy of maprotiline and aminophylline were statistically not significant (p > 0.05). In 18 patients maprotiline caused sedation and even somnolence. The authors conclude that maprotiline is an efficacious bronchodilator in patients with bronchospasm and is well tolerated by the patients.
Subject(s)
Bronchial Spasm/drug therapy , Maprotiline/therapeutic use , Adult , Aminophylline/therapeutic use , Drug Administration Schedule , Female , Humans , Male , Middle AgedABSTRACT
A effect of a single dose 400 micrograms misoprostol (Cytotec-Searle) on a degree of the bronchospasm relief has been investigated in 8 patients, and the results have been compared with those produced by aminophylline i.v. infusion in the rate of 500 mg/hour. Prior to and 10, 20, 30, 60, 90, 120, 150 and 180 minutes after administration of both drugs, the following parameters of pulmonary ventilation have been determined: VC, VC%, FEV1, FEV1%, MVV, and MEFR. The results have shown that misoprostol given in a single oral dose of 400 micrograms to patients with bronchospasm has the bronchodilating activity which is statistically significant. However, this activity is rather weak and significantly lower than that of intravenous aminophylline infusion.
